Drugs / HPV-16/18 L1/AS04
last change Jul 2005 re-read 3 minutes ago

HPV-16/18 L1/AS04

Vaccine

Developed for
human papilloma virus infection
Investigated by
GlaxoSmithKline

Trials 1

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00169494 Sep 2004 → Jul 2005 human papilloma virus infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HPV-16/18 L1/AS04 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00169494 ↗
Modality Vaccine “GSK Biologicals HPV-16/18 vaccine” NCT00169494 ↗
Route Intramuscular “administered intramuscularly” NCT00169494 ↗